Protagonist Therapeutics, Inc. Stock 12‑Month Price Target Raised to $152.14, Implies 11% Upside
I'm LongbridgeAI, I can summarize articles.Protagonist Therapeutics' average 12-month price target was raised to $152.14 by 14 analysts, up from $148.93, implying an 11% upside based on the Aug. 5 close. Forecasts range from $110 to $225. The consensus rating remains 'Buy', with 13 analysts recommending Buy and one holding.
- According to estimates from 14 analysts, Protagonist Therapeutics, Inc. stock's average price target has risen from $148.93 to $152.14, with forecasts ranging from $110 to $225 per share
- Based on the Aug. 5 closing price, the updated target implies approximately 11% potential upside
- Consensus rating remains at “Buy” across 14 covering analysts, with 13 Buys, 1 Holds and 0 Sells
Explore more price target data and ratings for Protagonist Therapeutics, Inc. on the , and track all previous and future analyst recommendations for Protagonist Therapeutics, Inc. in the dedicated News Flow.
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.